ZVRA Zevra Therapeutics Inc.
P/E
12.13
Forward P/E
11.55
Price/Sales
5.19
Beta
0.923
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Woodline Partners Takes 8.1% Zevra Stake, Following 53% Revenue Growth
Woodline Partners LP disclosed an 8.1% stake in Zevra Therapeutics in an August 14, 2026, regulatory filing. The investment firm holds 4,785,771 shares of...
Zevra Therapeutics Price Targets Climb, Following Massive Q2 Earnings Beat
HC Wainwright raised its 2027 earnings per share (EPS) estimate for Zevra Therapeutics from $0.46 to $0.55 on August 10. The firm maintained its Buy rating and...